FDA preps for upcoming ICCR
This article was originally published in The Rose Sheet
Executive Summary
Public meeting will be held June 19 in Rockville, Md. to provide information and receive comments related to International Cooperation on Cosmetics Regulations (ICCR), a voluntary effort between U.S., Japan, the EU and Canada to remove regulatory obstacles to international trade. FDA will go over topics to be discussed at second round of ICCR steering committee and expert working group meetings in Washington, D.C. the week of July 28, according to the agency's recent notice. In fall 2007, Senator John Kerry, D-Mass., lamented the public's exclusion from the first ICCR meeting in a letter to FDA Commissioner Andrew von Eschenbach (1"The Rose Sheet" Oct. 1, 2007, p. 3). An FDA document detailing the outcome of ICCR's first round of talks became available in March; FDA is accepting comments through July 2 (2"The Rose Sheet" March 10, 2008, In Brief)...
You may also be interested in...
Effort To Harmonize Cosmetics Regs Should Include Public Input – Sen. Kerry
FDA should take steps to ensure that the public can participate in an initiative to bring international cosmetics regulations closer to alignment, Senator John Kerry (D-Mass.) stated in a Sept. 26 letter to FDA Commissioner Andrew von Eschenbach
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.